Catherine Terret
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Jhaveri K, De Vita S, Crystal A, He W, Ji Y, Balbin A, Sheng Q, Kundamal N, Huober J, Takahashi S, Terret C, Duhoux F, Layman R, Cresta S, Yap Y, Juric D, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021
Aug 25, 2021A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Aug 25, 2021Clin Cancer Res 2021
Jhaveri Komal, De Vita Serena, Crystal Adam, He Wei, Ji Yan, Balbin Alejandro, Sheng Qing, Kundamal Nicole, Huober Jens, Takahashi Shunji, Terret Catherine, Duhoux Francois P, Layman Rachel M, Cresta Sara, Yap Yoon-Sim, Juric Dejan, Curigliano Giuseppe
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
Ravaud A, Cerny T, Terret C, Wanders J, Bui B, Hess D, Droz J, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. European journal of cancer (Oxford, England : 1990) 2005; 41:702-7.
Mar 1, 2005Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
Mar 1, 2005European journal of cancer (Oxford, England : 1990) 2005; 41:702-7
Ravaud Alain, Cerny Thomas, Terret Catherine, Wanders Jantien, Bui Binh Nguyen, Hess Dagmar, Droz Jean-Pierre, Fumoleau Pierre, Twelves Chris